Codexis (CDXS) Income from Continuing Operations (2010 - 2026)
Codexis' (CDXS) quarterly Income from Continuing Operations came in at 8704000.0 in Q1 2026, up 57.93% year-on-year from 5511396.67 in Q1 2025, and down 190.66% quarter-over-quarter from 9601000.0 in Q4 2025.
Codexis (CDXS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Codexis' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 8704000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 57.93% year-over-year to 8704000.0 in Q1 2026; TTM through Mar 2026 was 31990000.0, a 57.04% increase from a year earlier, with the FY2025 full-year figure at 43974000.0, up 32.63% from the prior year.
- Income from Continuing Operations slipped to 8704000.0 in Q1 2026 per CDXS's latest filing, from 9601000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9601000.0 in Q4 2025 and bottomed at 34908000.0 in Q3 2023.
- The 5-year median for Income from Continuing Operations is 11523000.0 (2023), against an average of 13399176.47.
- Across the five-year window, Income from Continuing Operations slumped 545.28% in 2022 and surged 192.53% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 12604000.0 in 2022, then soared by 42.94% to 7192000.0 in 2023, then tumbled by 44.27% to 10376000.0 in 2024, then jumped by 192.53% to 9601000.0 in 2025, then slumped by 190.66% to 8704000.0 in 2026.
- Per Business Quant, the three latest CDXS Income from Continuing Operations figures stand at 8704000.0 (Q1 2026), 9601000.0 (Q4 2025), and 19615000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Codexis | 180.63 Mn | 115.49 Mn | 13.18 Mn | -8.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.70 Mn |
| Dec 31, 2025 | 9.60 Mn |
| Sep 30, 2025 | -19.62 Mn |
| Jun 30, 2025 | -13.27 Mn |
| Mar 31, 2025 | -20.69 Mn |
| Dec 31, 2024 | -10.38 Mn |
| Sep 30, 2024 | -20.64 Mn |
| Jun 30, 2024 | -22.76 Mn |
| Mar 31, 2024 | -11.51 Mn |
| Dec 31, 2023 | -7.19 Mn |
| Sep 30, 2023 | -34.91 Mn |
| Jun 30, 2023 | -11.52 Mn |
| Mar 31, 2023 | -22.62 Mn |
| Dec 31, 2022 | -12.60 Mn |
| Sep 30, 2022 | -9.99 Mn |
| Jun 30, 2022 | -2.64 Mn |
| Mar 31, 2022 | -8.36 Mn |
| Dec 31, 2021 | -10.19 Mn |
| Sep 30, 2021 | 2.24 Mn |
| Jun 30, 2021 | -4.27 Mn |